



ERA CoBioTech (ERA-Net Cofund on Biotechnologies)

ACHEMA2018

Kick-off session: "Biotechnology
for a sustainable bioeconomy"

Title: ComRaDes

Project name: COMputation for RAtional DESign:
From lab to industry with success

Name: Henk Noorman



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant 722361

Frankfurt am Main, 13.06.2018



SINOCHEM




DSM

DSM Sinochem Pharmaceuticals

- Partners:
 - DSM Sinochem Pharmaceuticals, NL
 - Technical University Delft, NL
 - University Liege, B
 - Syngulon, B
 - University Stuttgart, D

- Total project budget: 2 M€

- Project start: July 25, 2018

 TU DelftLIEGE université
Gembloux
Agro-Bio TechUniversität
Stuttgart

- Sustainable production and conversion of different types of feedstocks and bioresources into added value products
- Scientific approaches:
 - Synthetic biology
 - Systems biology
 - Bioinformatic tools
 - Biotechnological approach(es)

Project objectives (problem to be solved):

- Moving to bio-based economy
- Use of microorganisms to convert renewable feedstocks into added-value products




Figure 3 – Analogous Model of a Biobased Product Flow-chart for Biomass Feedstocks

Project objectives (problem to be solved):

- Moving to bio-based economy
- Use of microorganisms to convert renewable feedstocks into added-value products

Titer
Rate
Yield

Productivity (g/l.h)

Lactic acid: 150 (cell recycling)
 Ethanol: 82 (ISPR, cell recycling)
 Sorbitol: 38
 Gluconate: 19 (cell retention, pure O₂)
 Succinate: 15 (cell retention, ISPR)
 1-butanol: 10 (immobilized cells)
 Valine: 6 (metabolic engineering)

Yield (g/g, % of max)

Lactic acid: 1.00 (~100%)
 Citric acid: 0.88 (80%)
 Acetic acid: 0.80 (80%)
 Glutamate: 0.60 (80%)
 Ethanol: 0.51 (96%)
 Lysine: 0.44 (74%)
 1-Butanol: 0.36 (85%)
 Methane: 0.27 (~100%)

Titer (g/l)

Gluconate: 504
 Sorbitol: 300
 Xylitol: 244
 Erythritol: 240
 Citric acid: 240
 Mannitol: 237
 Lactate: 231
 Valine: 227
 Acetic acid: 203
 Ethanol: 170
 2,3 Butanediol: 152
 Succinate : 146
 1,3-Propanediol: 141
 Glutamate: 141
 Threonine: 118
 1,4 Butanediol: 115

**Published best key performance
 Indicators of commercial products**

- Project objectives (problem to be solved):
 - Moving to bio-based economy
 - Use of microorganisms to convert renewable feedstocks into added-value products
 - Takes long time (5 years), costly (10 M€)

- Project objectives (problem to be solved):
 - Moving to bio-based economy
 - Use of microorganisms to convert renewable feedstocks into added-value products
 - Takes long time (5 years), costly (10 M€)
 - Bottleneck of bringing synthetic biology innovations to the factories



Scale-up

Lab vs. Industry:


Conditions not the same!



Scale-down



- Project objectives (problem to be solved):
 - Moving to bio-based economy
 - Use of microorganisms to convert renewable feedstocks into added-value products
 - Takes long time (5 years), costly (10 M€)
 - Bottleneck of bringing synthetic biology innovations to the factories



Scale-up fail

Lab vs. Industry:


Conditions not the same!



- Project objectives (problem to be solved):
 - Moving to bio-based economy
 - Use of microorganisms to convert renewable feedstocks into added-value products
 - Takes long time (5 years), costly (10 M€)
 - Bottleneck of bringing synthetic biology innovations to the factories


Bioprocess Development must become

- Cheaper: 10 M€ → 2 M€
- Faster: 5 y → 1 y
- Better: TRY (titer, rate, yield) closer to the maximal possible
- Less risky: no full-scale problems




Lagrangian CFD approach

- Scientific approach: High-precision scale-down and improved scale-up performance via computation-driven, rational design



- Track many microbes, register their adventures
 - Developed by Lapin and Reuss (2004, 2006)


Track $\sim 10^3 - 10^5$ particles
Record “Lifelines”




Glucose uptake (q_s) from the organism point of view

Industry to lab: lifeline scale-down



1. Simulate reactor, collect lifelines




2. Analyze lifelines:
Fluctuation statistics




3. Invert statistics:
Scale-down design




Impact of multiple sources of extracellular (bioreactor) noise



Sugar concentration and uptake rate



Oxygen concentration and uptake rate





Shear rate gradients


Cumulative effects - intensified impact




Impact of extracellular (bioreactor) noise on intracellular (biological) noise




t = 0 min



t = 50 min



t = 100 min



Colony 1 with heterogeneous GFP expression

Colony 2 without GFP expression

Work package structure

WP 0 - Overall coordination: Delft/Noorman, supported by DSP/van de Sandt

Large-scale bioreactor data, research strain *S. cerevisiae*, methods, knowhow, LCA input

DSP*: large-scale bioreactor data, research strain *P. chrysogenum*, methods, knowhow, LCA input

* DSM Sinochem Pharmaceuticals

DSM: coordination
WP Integration
Ethical/societal aspects
Exchange of students
Project management
Reporting

WP 4 – Characterization of microbial population dynamics in large scale-conditions: Liege/Delvigne

Syngulon: Strain evolution and synthetic biology

Scale-up to pilot
Validation

Single cell/population modeling and experiments
Selected scale-down experiments

WP 1 – Computation and scale-down design for industrial fermentors: Delft/Noorman

Transfer validated models to industry

Euler-Lagrange large-scale computation (two systems), including gas phase, kinetics
Design of scale-down simulators

WP 2 – Development and validation of compact biological reaction kinetic models: Delft/vGulik

Kinetic/structured modeling
Single reactor scale-down experiments
Use of 'omics' diagnostic tools
Strain evolution/synthetic biology

WP 3 – Studying large-scale conditions by wet- and dry-lab approaches: Stuttgart/Takors

Euler-Lagrange computation, including cell population modeling
Kinetic/structured modeling
Dual reactor scale-down experiments



Penicillium chrysogenum



Saccharomyces cerevisiae

**P1 DSM Sinochem Pharmaceuticals
/ van de Sandt**

**Linked 3rd party: DSM Food Specialties
/ Noorman**


**P4 TU Delft
/ van Gulik**

**P2 U Stuttgart
/ Takors**

**P4 TU Delft
/ Noorman**

**P3 U Liège
/ Delvigne**

**P5 SYNGULON
/ Gabant**



- 1: *P. chrysogenum* strains
- 2: industrial conditions
- 3: *S. cerevisiae* strains
- 4: industrial conditions
- 5: *cfD* approaches
- 6: kinetic models
- 7: metabolomics data
- 8: proteomics data
- 9: engineering of robust strains
- 10: analysis of population heterogeneity

Outcome:
Ab initio, in silico scale-up design



- Data management plan: Will be hosted by the DSM data platform with back-up at TU Delft
- Dissemination & Communication Manager: Prof. Frank Delvigne, covering following activities:
 - establishing and updating dissemination and outreach strategy, plan and dissemination;
 - dealing with open access to publications;
 - giving support while implementing the communication activities;
 - networking and community building;
 - raising target groups awareness about project results.

● *Outcomes to be achieved:*


- accelerating the bioprocess development including plant start-up by at least 20% (e.g. from 5 to 4 years), which could after 10 years further develop into a factor 5 (from 5 to 1 year).
- developing guidelines for constructing strains such that they are robust enough for harsh production conditions
- the early identification of scale-up sensitive properties of novel producers to ensure efficient use of manpower and research capacities
- reducing of the order of 10's of tonnes of CO₂ emission per large-scale fermentation
- reducing the energy requirements of at least 10%, i.e. in the order of 10 MWh, per run executed on industrial scale
- reducing by at least 20% the development budget (e.g. from 10 M€ to 8 M€), which could after 10 years further advance to a factor 5 (from 10 to 2 M€)




- *Planned implementation and exploitation of results:*

The projects should fall within TRL₃₋₆: ComRaDes uses two real life examples to develop and demonstrate its approach. Its final delivery is a working framework, that can be used by industry not only for the two cases used but in principle for 'any' engineered micro-organism and its application in sustainable biotech. The research part of ComRaDes is at TRL 3-4, the final delivery at TRL 5-6. The presence of DSM Sinochem Pharmaceuticals as active partner in our consortium guarantees focus on reaching TRL 6, i.e. demonstrating our approach on existing processes from industry.

Artist impression





SINOCHEM



DSM

DSM Sinochem Pharmaceuticals


- Coordinator: Henk Noorman, henk.noorman@dsm.com
- Partners:
 - Emile van de Sandt, DSM Sinochem Pharmaceuticals, NL
 - Walter van Gulik, Technical University Delft, NL
 - Frank Delvigne, University Liege, B
 - Philippe Gabant, Syngulon, B
 - Ralf Takors, University Stuttgart, D



LIÈGE université

Gembloux
Agro-Bio Tech

SYNGULON

Microbial
fermentation
technologies
for bio-based
productsUniversität
Stuttgart

